MINNEAPOLIS–(BUSINESS WIRE)– DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its second quarter 2023 financial results will be released after the markets close on Monday, August 14th. DiaMedica will host a live…Read More
DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15 2023
